This page is free to read, and it stops after 5 rows. Those are the 5 most recently posted filings for this company, out of 8. Reading the whole list, and what each filing says: its issues, the agencies contacted and the lobbyists named, is part of the subscription. So is sorting the list by the reported amount. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Lobbying reported per quarter

reported amounts per quarter, latest version of each report

There are two charts here because there are two different amounts. A lobbying firm reports income: what it was paid. A company that lobbies for itself reports expenses: what it spent, under one of three accounting methods it picks itself. Both appear under this company, and they are not the same measurement — so they are never added, not in a bar and not in a total.

Reported income: what lobbying firms reported receiving from this company's clients, per quarter.

Reported expenses: what this company reported spending on its own lobbying, per quarter, under the accounting method it picked itself.

Before 2025, these bars cover only the lobbying relationships that were still active in 2025 or later. Engagements that ended earlier are not included, so those years may be higher than shown.

Reported income

Q1Q2Q3Q4
$0$50k$100k2024: $0 Q1, $0 Q2, $0 Q3, $50k Q420242025: $60k Q12025

Reported expenses

Q1Q2Q3Q4
$0$250k$500k2024: $220k Q1, $30k Q2, $80k Q3, $110k Q420242025: $330k Q12025

Recent activity

Register facts only. Everything on this page comes from filings made under the Lobbying Disclosure Act of 1995 and kept by the Secretary of the Senate. We read the filings, we link a client to a listed company where a reviewed rule allows it, and we add nothing else. No score, no ranking and no judgement is attached to lobbying on this site. See the methodology and about this site.

5 of 8 filings
The most recently posted lobbying filings for RARE
RegistrantFilingAmountPosted SourceRegistrantAmountFilingAll amountsPosted Source
ULTRAGENYX PHARMACEUTICAL INC.for ULTRAGENYX PHARMACEUTICAL INC.1st Quarter - Report1st Quarter 2025$330,000expenses (A)posted Apr 21, 2025Apr 21, 2025LD-2 at lda.govULTRAGENYX PHARMACEUTICAL INC.for ULTRAGENYX PHARMACEUTICAL INC.$330,000expenses (A) · Apr 211st Quarter - Report1st Quarter 2025$330,000expenses (A)Apr 21, 2025LD-2 at lda.gov
MEHLMAN CONSULTING, INC.for ULTRAGENYX PHARMACEUTICAL, INC.1st Quarter - Report1st Quarter 2025$60,000incomeposted Apr 17, 2025Apr 17, 2025LD-2 at lda.govMEHLMAN CONSULTING, INC.for ULTRAGENYX PHARMACEUTICAL, INC.$60,000income · Apr 171st Quarter - Report1st Quarter 2025$60,000incomeApr 17, 2025LD-2 at lda.gov
ULTRAGENYX PHARMACEUTICAL INC.for ULTRAGENYX PHARMACEUTICAL INC.4th Quarter - Report4th Quarter 2024$110,000expenses (A)posted Jan 20, 2025Jan 20, 2025LD-2 at lda.govULTRAGENYX PHARMACEUTICAL INC.for ULTRAGENYX PHARMACEUTICAL INC.$110,000expenses (A) · Jan 204th Quarter - Report4th Quarter 2024$110,000expenses (A)Jan 20, 2025LD-2 at lda.gov
MEHLMAN CONSULTING, INC.for ULTRAGENYX PHARMACEUTICAL, INC.4th Quarter - Report4th Quarter 2024$50,000incomeposted Jan 20, 2025Jan 20, 2025LD-2 at lda.govMEHLMAN CONSULTING, INC.for ULTRAGENYX PHARMACEUTICAL, INC.$50,000income · Jan 204th Quarter - Report4th Quarter 2024$50,000incomeJan 20, 2025LD-2 at lda.gov
ULTRAGENYX PHARMACEUTICAL INC.for ULTRAGENYX PHARMACEUTICAL INC.3rd Quarter - Report3rd Quarter 2024$80,000expenses (A)posted Oct 21, 2024Oct 21, 2024LD-2 at lda.govULTRAGENYX PHARMACEUTICAL INC.for ULTRAGENYX PHARMACEUTICAL INC.$80,000expenses (A) · Oct 21, 20243rd Quarter - Report3rd Quarter 2024$80,000expenses (A)Oct 21, 2024LD-2 at lda.gov

The link between the client names above and RARE is a reviewed rule of ours, not something the filing states: an LD-2 names a client and carries no ticker, no CIK and no LEI.